Nasdaq · Healthcare
XOMA Royalty Corp (XOMA)
As-reported financials and recent SEC filings for XOMA Royalty Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$52.1M
Net income
$31.7M
Net margin
60.8%
Diluted EPS
$1.46
ROE
37.8%
P/E (TTM)
—
Market cap
—
Debt / equity
1.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $52.1M | $28.5M | $2.6M | $4.2M | $36.5M |
| Gross profit | — | — | — | — | — |
| Operating income | $11.4M | $-40.0M | $-41.8M | $-17.4M | $17.5M |
| Net income | $31.7M | $-13.8M | $-40.8M | $-17.1M | $15.8M |
| Diluted EPS | $1.46 | $-1.65 | $-4.04 | $-0.00 | $0.69 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
DEFA14A2026-06-12
View on EDGAR →8-K2026-06-12
View on EDGAR →DEFM14A2026-06-10
View on EDGAR →42026-05-26
View on EDGAR →42026-05-26
View on EDGAR →42026-05-26
View on EDGAR →42026-05-26
View on EDGAR →42026-05-26
View on EDGAR →Largest Healthcare peers
Go deeper on XOMA
Search XOMA Royalty Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.